ADVANCES IN NATURAL EXTRACTS USED FOR ANTIBIOTIC-RESISTANT BACTERIA TREATMENT: THE GRAM-NEGATIVE CASES
Background: Infectious diseases are a global problem, the second human cause of death. Infectious diseases caused by pathogenic bacteria have been treated with a high degree of efficacy. However, even when the 20th century was considered the “golden age” of antibiotics, bacteria developed a different resistance mechanism to antibiotics. In 2017, the WHO issued an alert about 12 bacteria with an urgent need to develop new antibiotics. Aims: The aim of the present review is to analyze the current knowledge of the antibacterial activity of natural extract-based treatments against the pathogens listed by WHO. Methods: A systematic review of the literature in PubMed was performed to search for publications describing the use of natural extracts as antibiotics over bacteria. We focused on the Gram-Negative group. The exclusion criteria consisted of limiting papers on natural extracts tested over the bacteria culture related to eight selected bacteria, according to an alert issued by WHO in 2017, and seven plant extracts. Results: All the Gram-Negative bacteria listed in 2017 by WHO have been treated, with different degrees of advance, with some of the plant extracts and plant-based compounds reviewed. In general, the first approach is using inhibition disks applied over the bacterial biofilm in solid culture media. Discussion: While Salmonellae and P. aeruginosa have been extensively studied, over N. gonorrhoeae, A. baumannii have been tested with fewer natural extracts. Edible herbs are more often used, as well as artemisa and wine byproducts. In all cases, they are in the early stages of study, not being tested in patients at present. Conclusions: Plant extracts and plant-based compounds are effective as antibacterial, with minimal effects on the host cell. Furthermore, they are sustainable, environmentally friendly, and renewable.
Read ArticleE-SELECTIN AS A BIOMARKER IN FEMALE PATIENTS WITH Β-THALASSEMIA IN AL- NAJAF PROVENCE, IRAQ
E-selectin, as identified (CD62E), is expressed on endothelial cells after stimulation with inflammation cytokines. β-Thalassemia diseases (βT) and early diagnosis are of utmost significance in the entire world population. This study was performed in the Thalassemia Center of the Al-Zahraa Educational Hospital in Al-Najaf Province, Iraq, on sixty-nine with β-thalassemia (54 βT major and 15 βT Intermedia) aged 8-40 years who transfused blood. Compared to 20 healthy volunteers as a control group. In both βT patients and healthy groups were assessed serum E-selectin levels. It was investigated the relationship with RBC, Hb, PCV, WBC, PLT, BMI, splenic status, iron, and ferritin levels. The results revealed a significant (P<0.05) decreased values of HB, RBC, P.C.V, and BMI. In contrast, values of WBC, PLT, Iron, and Ferritin were significantly increased in βT patients as compared to the healthy control groups. A significant (P<0.05) increase in serum E- Selectin level in βT patients (20.55±0.47) ng/ml to compare with the healthy group (9.16±0.50) ng/ml. Furthermore, it was a significant decrease in groups of βT major (19.87±0.42) ng/ml more than in βT intermedia (23±1.42) ng/ml. E-Selectin revealed a significant increase (P<0.05) in progress age and associated with splenectomies and underweight groups compared to splenectomies and the normal weight groups, respectively. Also, E-Selectin levels significantly positively correlated with WBC, PLT value, iron, and Ferritin levels. However, it was no significant with RBC, PCV, Hb. As a conclusion from this study, E- Selectin is an important biomarker in β-thalassemia patients can be identified as the complications associated with iron overload, inflammatory process, and endothelial dysfunction in βT disease.
Read ArticleD-DIMER A RISK FACTOR ASSOCIATED WITH C-REACTIVE PROTEIN FOR PREDICTING THE SEVERITY OF INFECTION BY COVID-19
Background: COVID-19, caused by SARS-CoV-2, has unresolved mortality risk factors and clinical course, highlighting the need for further research. Aims: The study aimed to asses D-dimer and C-Reactive Protein (CRP) as the risk factors for severity covid-19 and who are less capable of surviving. Methods: A retrospective study conduct of COVID-19 in adult inpatients aged >20 at Al-sadder and Alamal Hospital in Iraq. Demographics, clinical trials, treatments, and viral RNA samples were analyzed. The study involved 100 patients, with 67 discharged and 33 hospitalized died. The majority of the participants 45% were aged < 40, but 55% were aged >40 years. Results: A significant and 57% were male 37(55.2%) Survivor vs. 20 (60.6%) non-survivor, p=0.024), more than 43% were female (30(44.8%) Survivor vs. 13(39.4%) non-survivor, p=0.010. Patients had underlying comorbidities (66%), survivor 37(55%), and non-survivor 29(87%). The most prominent comorbidity in non-survivors more than survivors was diabetic mellitus 85%, asthma 58%, stroke 48%, renal failure 42%, heart strake 33%, and hypertension 18%. The study found significant differences in WBC, lymphocyte count, D-dimer, Ferritin, CRP, and LDH levels in non-survivors compared to survivor patients, with a positive correlation between D- dimer and these parameters. The ROC analysis curve showed CRP with a high AUC of 80.2%, 87.9% sensitivity, and 37.3% specificity, while D-dimer and LDH had AUCs of 0.74.9 and 70%, respectively. Discussion: The study found that older age, higher d-dimer, ferritin, CRP, and LDH are associated with disease severity and higher mortality risk in adult COVID-19 patients. Conclusions: These biomarkers could aid in early detection of disease progression signs and better patient management
Read Article